Tesla, Inc. is a U.S.-based electric vehicle and energy company that designs, manufactures and sells battery EVs, energy storage systems and charging solutions, alongside software and autonomous driving features. It competes globally with legacy automakers shifting to EVs (Volkswagen, Toyota, GM, Ford), high-volume EV leaders (BYD), and newer pure-play peers (NIO, Rivian, Lucid), while also contending with tech-led competition in autonomy and AI capabilities.

Financially, Tesla reports trailing-12-month revenue of $92.72B and net income of $5.88B (profit margin 6.34%), supported by $16.21B gross profit and $11.44B EBITDA. Growth has cooled, with quarterly revenue down 11.80% year over year and quarterly earnings down 16.30%. Liquidity remains solid with $36.78B cash versus $13.13B total debt, a 2.04 current ratio, and $15.77B operating cash flow ($1.4B levered free cash flow). Diluted EPS is 1.69; ROE is 8.18% and ROA is 2.96%. Shares outstanding total 3.33B; the stock’s beta is 2.07. Over the past 52 weeks, TSLA is up 74.18% (S&P 500 +15.54%), trading in a 212.11–488.54 range.

CSL Limited (ASX: CSL) is an Australian biopharmaceutical company focused on plasma‑derived therapies (CSL Behring), influenza vaccines (CSL Seqirus) and specialty medicines for cardio‑renal and iron deficiency (CSL Vifor). It competes with global plasma and vaccine players such as Grifols, Takeda, Sanofi and Pfizer across key therapeutic markets.

Financially, CSL reports revenue (ttm) of 15.56B and net income of 3.00B, supported by a 19.30% profit margin and 18.83% operating margin. EBITDA totals 4.91B, operating cash flow 3.56B and levered free cash flow 1.88B. The balance sheet shows 2.16B in cash versus 11.5B in total debt (debt/equity 53.71%) and a 2.46 current ratio; ROE is 15.37%. Quarterly revenue grew 4.90% year over year and quarterly earnings increased 34.30% year over year. The forward dividend yield is 2.28% on a 4.52 distribution with a 45.49% payout ratio, and the shares have fallen 32.00% over 52 weeks with low beta at 0.26.

Geely Automobile Holdings (0175.HK) enters September 2025 with improving scale but tight margins, setting the stage for a cautious three‑year outlook to September 2028. The company reports trailing revenue of 271.69B, net income of 15.06B and a profit margin of 5.57%, supported by total cash of 69.11B against total debt of 24.11B. Quarterly revenue grew 17% year over year, but quarterly earnings growth declined 60.80%, highlighting pricing pressure and mix effects. Shares closed near 18.20, up 73.38% over 12 months, with a 1.81% forward dividend yield and a 20.44% payout ratio. With a current ratio of 0.95, operating cash flow of 22.59B and levered free cash flow of 37.37B, we focus on margin trajectory, product competitiveness and capital discipline as key determinants of returns.

Mazda Motor Corporation’s stock has rebounded toward its 52‑week highs after a sharp late‑March selloff, closing at ¥1,093 on September 24, 2025. The cash-rich balance sheet (¥1.01T cash vs. ¥716.59B debt) and positive free cash flow (levered FCF ¥102.44B) underpin a 4.94% forward dividend yield ahead of the September 29 ex‑dividend date. Fundamentals remain mixed: trailing 12‑month revenue is ¥4.91T, but quarterly revenue growth is down 8.8% year over year, the operating margin is negative (‑4.19%), and net margin is slim (0.45%). Valuation screens as value‑oriented with price‑to‑book of roughly 0.4x and price‑to‑sales near 0.14x based on reported metrics. With a low beta (0.48) and liquidity support (current ratio 1.52), the setup is about execution—stabilizing sales and repairing margins—against an industry backdrop that remains uncertain into the fall selling season.